Back to search results

Learning Amyloid and Tau Results in Alzheimer's Disease

This observational study is looking at how people react to learning their personal test results for amyloid and tau, which are markers linked to Alzheimer's disease. Researchers want to understand if knowing these results changes how you feel, your behaviors, or your thinking abilities over time. The study will also explore what factors might influence these reactions. You may be able to join if you are between 45 and 89 years old, are already part of the Wisconsin Registry for Alzheimer's Prevention (WRAP) or the Alzheimer's Disease Research Center Clinical Core (ADRC), and have been determined to have normal thinking skills. The study will measure changes in your well-being, how you perceive stigma, and your overall quality of life at several points over 18 months.

Study design
This is an observational study involving 240 participants. It is a single-center study where all participants will receive the same intervention.
What's involved
You will complete surveys at four different times after learning your Alzheimer's biomarker test results. These assessments will occur at 1 month, 6 months, 12 months, and 18 months.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for 18 months after learning their test results.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07222930

Learning Amyloid and Tau Results

Enrolling by Invitation
Not specifiedAges 45–89Observational
University of Wisconsin, Madison
~240 participants
Updated 2026-06-24 on ClinicalTrials.gov
What's tested:Disclose amyloid, tau resultsFollow-up Assessments

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Impact of Neuroimaging in Alzheimer's Disease (INI-AD) Score
Measured over 1 month, 6 months, 12 months, 18 months
+3 more outcomes measured

Conditions

Alzheimer Disease

Explore related trials

Alzheimer's DiseaseMild cognitive disorder

NCT07222930

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • University of Wisconsin

    Madison, Wisconsinno site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Lindsay Clark, PhD · PRINCIPAL_INVESTIGATOR · UW School of Medicine and Public Health

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Willing to provide informed consent.
Willing to comply with all study procedures and be available for the duration of the study.
Individuals at least 45 years of age.
Enrolled in Wisconsin Registry for Alzheimer's Prevention (WRAP) or Alzheimer's Disease Research Center Clinical Core (ADRC)
Previously adjudicated as cognitively unimpaired having mild cognitive impairment (MCI), or impaired but do not meet diagnostic criteria for mild cognitive impairment or dementia (classified as "Impaired-Not MCI" by the WRAP and ADRC cohorts) at their last WRAP or ADRC study visit at the time of enrollment into this study
Have completed or able to complete amyloid and/or tau PET scans as part of a UW Alzheimer's Research Study

Exclusion

Diagnosis of dementia at the time of enrollment as determined by the most recent parent WRAP/ADRC study visit diagnostic consensus conference using standard NIA-AA 2011 diagnostic criteria. Participants who develop dementia after enrolling into this study may remain enrolled if they maintain decisional capacity and are able to follow study instructions and procedures.
Individuals who lack decisional capacity to provide informed consent as determined by significant difficulty in understanding materials and information about study procedures during recruitment and/or informed consent discussions.
Not suitable for study participation due to other reasons at the discretion of the investigators.

What this trial measures

  • Impact of Neuroimaging in Alzheimer's Disease (INI-AD) Score1 month, 6 months, 12 months, 18 months

    Test-related distress will be assessed using the INI-AD instrument. Score range from 0-80 where higher scores indicate increased negative impact of test.

  • Stigma Impact Scale (SIS) Score1 month, 6 months, 12 months, 18 months

    Items are rated on a 4-point Likert scale ranging from strongly agree (4) to strongly disagree (1), and a fifth option of "not applicable" with higher total scores (24-96) indicating higher perceived stigma.

  • Control, Autonomy, Self-Realization, and Pleasure (CASP-12)baseline, 1 month, 6 months, 12 months, 18 months

    This is a quality of life measure scored from 0-36 where higher scores mean better quality of life.

  • Future Time Perspective Scalebaseline, 1 month, 6 months, 12 months, 18 months

    Scores are from 1-7 where higher scores indicate higher engagement.